GW501516 (also known as GW-501,516, GW1516, GSK-516 and on the black market as Endurobol) is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s, was entered into clinical development as a drug candidate for metabolic diseases and cardiovascular diseases, and was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs.

CAS：317318-70-0
中文别名：2-(4-((2-(4-(三氟甲基)苯基)-5-甲基噻唑-4-基)甲基硫基)-2-甲基苯氧基)乙酸;
英文别名：2-methyl-4-(((4-methyl-2-(4-(trifluoromethyl)phenyl)-5-(thiazolyl)methyl)thio)phenoxy)acetic acid;Endurobol;2-(2-BROMOPHENYL)-3\'-TRIFLUOROMETHYLACETOPHENONE;{2-Methyl-4-{{4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl}methylthio}phenoxy}acetic acid;GW1516;2-(4-((2-(4-(Trifluoromethyl)phenyl)-5-methylthiazol-4-yl)methylthio)-2-methylphenoxy)acetic acid;UNII-7I2HA1NU22;GW 501516;2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid;
分子式：C21H18F3NO3S2
分子量：453.498
精确质量：453.068
Psa：112.96
Logp：6.2014

MDL号：MFCD09033000

外观与性状：白色固体
密度：1.426 g/cm3
沸点：584.543ºC at 760 mmHg
闪点：307.321ºC
折射率：1.619